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Recent studies indicate that the selected micro-and
macro-elements and vitamins may significantly influence
the risk of cancer. Folic acid is a vitamin B which plays
an important role in several processes in organism.
Folates are important cofactors in the transfer and utili-
zation of one-carbon-groups and play a key role in the
remethylation of methionine thus providing essential
methyl groups for numerous biological reactions.
Furthermore, folates donate one-carbon units in the
process of DNA-biosynthesis with implications for the
regulation of gene expression, transcription, chromatine
structure, genomic repair and genomic stability. Defi-
ciency of folic acid has been reported to be associated
with numerous disorders, including heart disease, stroke
and cancers.
The MTHFR gene produces a key enzyme in folate
metabolism which catalyses the reactions essential for
nucleotide biosynthesis and DNA methylation.
The aim of study was to analyze an association of folic
acid concentrations and genetic variants in the MTHFR
gene with breast cancer risk in patients with BRCA1
mutation.
Study group consisted of 155 breast cancer patients and
155 healthy women from the paired control group
matched to cases by year of birth, cancer family history,
adnexectomy, smoking. From all individuals blood sample
was collected and from cancer cases was taken before
treatment. Folic acid concentration was quantitatively
measured in blood plasma by HPLC chromatography
(Flexar HPLC, Perkin Elmer). Two functional SNPs in the
MTHFR gene, 677 C>T (rs1801133) and 1298 A>C
(rs1801131), both associated with reduced enzyme activity,
have been tested by TaqMan on LightCycler 480.(Roche
Diagnostic). Individuals were divided into four quartiles
depending on folic acid concentration and number of
cases and controls in each quartile was compared. Analysis
was made depending on menopausal status defined as ≤
50 and >50 years old.
In a group of >50 years old, individuals classified in the
first quartile (<17,35μmol/l) had a lower risk of breast
cancer than patients with higher folate level. Whereas in
a group of ≤50 years old, individuals classified in the 3
quartile (24,35 – 31,88 μmol/l ) had a significantly lower
risk of breast cancer than those with folate level between
32,02 – 54,42 μmol/l. Analysis of correlation between the
level of folic acid and genetic variants 677 C/T and 1298
A/C in the MTHFR gene performed in 2 groups (>50
and ≤50 years) revealed:
- for carriers of 1298 nCC and ≤50 years old signifi-
cantly lower risk of breast cancer in individuals classified
between 16,6-31,88 μmol/l in comparison to patients
with lower and higher folate level.
- for carriers of 677 CC and ≤50 years old lower risk of
breast cancer in individuals classified between 19,86-
32,02 μmol/l than patients with lower and higher folate
level.
- for carriers of 677nCC and ≤50 years old signifi-
cantly lower risk of breast cancer in individuals classified
between 5,94-14,8 μmol/l in comparison to patients with
higher folate level.
- for carriers of 1298 AA and >50 years old lower risk
of breast cancer in individuals classified in the first
quartile (<18,6μmol/l) in comparison to patients with
higher folate level.
- for carriers of 1298 nCC and >50 years old lower
risk of breast cancer in individuals classified in the first
quartile (<17,11μmol/l) in comparison to patients with
higher folate level.
- for carriers of 677 CC and >50 years old lower risk
of breast cancer in individuals classified in the first
quartile (<18,62μmol/l) in comparison to patients with
higher folate level.
- for carriers of 677 nCC and >50 years old lower risk
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quartile (<17,1μmol/l) in comparison to patients with
higher folate level.
We can conclude that concentration of folic acid in the
range of 18 - 32 μmol/l is associated with lower risk of
breast cancer for women ≤50 years, with the possible
exception for 677 nCC (CT+TT) where the lower risk of
breast cancer is classified between 5,94-14,8 μmol/l.
Concentration of folic acid lower than 17 μmol/l is
associated with lower risk of breast cancer for women
>50 years.
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